Ganirelix is a synthetic peptide that blocks the pituitary receptor for gonadotropin-releasing hormone (GnRH). It is an FDA-approved prescription drug, first labeled in the US as Antagon and now marketed as ganirelix acetate and Fyremadel. This guide covers its structure, mechanism, labeled use, key trials, side effects and regulatory status. Every source was checked on November 17, 2026.
Quick answer: Ganirelix blocks GnRH receptors in the pituitary gland, so LH and FSH release falls quickly and reversibly. Its approved use is limited to assisted reproduction. In its main trials, premature LH surges were rare and ovarian hyperstimulation was less common than with GnRH agonists. Pregnancy rates were numerically lower in those trials.
Vitrapep does not sell ganirelix; this page is a reference summary of published research and regulatory information. It is not medical advice.
What is ganirelix?
Ganirelix is a modified version of GnRH, the brain hormone that starts the reproductive hormone chain. The current label calls it “a synthetic decapeptide with high antagonistic activity against naturally occurring gonadotropin-releasing hormone (GnRH)” (ganirelix acetate label, 2026). A decapeptide is a chain of ten amino acids. The label says it differs from natural GnRH at positions 1, 2, 3, 6, 8 and 10.
PubChem lists the sequence as Ac-D-2Nal-D-Phe(4-Cl)-D-3Pal-Ser-Tyr-D-hArg(Et,Et)-Leu-hArg(Et,Et)-Pro-D-Ala-NH2 (PubChem CID 16130957). Several of these building blocks are synthetic, not found in natural GnRH. PubChem also lists Antagon and Orgalutran as synonyms.
Ganirelix: key facts
| Fact | Detail |
|---|---|
| Structure | Synthetic decapeptide; GnRH analog with substitutions at positions 1, 2, 3, 6, 8 and 10 |
| Class | GnRH antagonist |
| Molecular formula | C80H113ClN18O13 |
| Molecular weight | 1570.3 g/mol (PubChem); 1570.4 as anhydrous free base (label) |
| First FDA approval | July 29, 1999 (NDA 021057, first labeled as Antagon) |
| Brand names | Antagon (original US name); Fyremadel; generic ganirelix acetate |
Drugs@FDA lists Organon’s NDA 021057 with an original approval date of July 29, 1999 (Drugs@FDA). The 1999 label carried the name Antagon (FDA, 1999). Fyremadel, from Ferring, is approved under a generic application, ANDA 204246 (Fyremadel label, 2026).
How does ganirelix work?
The pituitary gland releases LH and FSH when GnRH reaches its receptors. A surge of LH triggers ovulation. Ganirelix “acts by competitively blocking the GnRH receptors on the pituitary gonadotroph and subsequent transduction pathway,” the label states.
The label lists four features of the effect:
- “It induces a rapid, reversible suppression of gonadotropin secretion.”
- Suppression of LH is “more pronounced than that of FSH.”
- No initial release of the body’s own gonadotropins has been detected.
- After it stops, “pituitary LH and FSH levels are fully recovered within 48 hours.”
These label statements describe human pharmacology. GnRH agonists such as leuprolide act differently, and our gonadorelin guide covers natural GnRH.
The early chemistry was done in animals and cells. Syntex chemists described ganirelix in 1992 among antagonists designed to release less histamine (Nestor et al., 1992). The lead compounds strongly suppressed ovulation in rats. They showed low histamine release in laboratory tests.
What is ganirelix approved for?
The label gives one indication: “the inhibition of premature LH surges in women undergoing controlled ovarian hyperstimulation.” The Fyremadel label uses the same wording. Controlled ovarian hyperstimulation is part of fertility treatment such as in vitro fertilization. A premature LH surge can trigger ovulation too early in that process.
The label warns that it “should be prescribed by physicians who are experienced in infertility treatment.” It adds that pregnancy must be excluded before treatment starts. No other use is labeled.
What did the key trials show?
The label rests on two well-controlled studies. One was a multicenter, double-blind study in 332 patients. The other was a multicenter, open-label, randomized study with 463 ganirelix-treated subjects and a GnRH agonist reference treatment. In that study, premature LH surges occurred in “less than 1% of subjects.” The ongoing pregnancy rate was 20.3% per attempt. All data below are from humans.
European trial (2000). This open-label, randomized, multicenter trial enrolled 730 women, assigned 2 to 1 to ganirelix or the agonist buserelin (Borm and Mannaerts, 2000). LH rises occurred in 2.8% with ganirelix and 1.3% with buserelin. Ongoing pregnancy rates per attempt were 20.3% and 25.7%. OHSS occurred in 2.4% and 5.9%. Fertilization rates were 62.1% in both groups.
North American trial (2001). This phase 3, open-label, randomized trial enrolled 313 women and compared ganirelix with the agonist leuprolide (Fluker et al., 2001). Mean eggs retrieved were 11.6 and 14.1. Clinical pregnancy rates per attempt were 35.4% and 38.4%. Moderate local reactions occurred in 11.9% with ganirelix and 24.4% with leuprolide.
Class-level review (2016). A Cochrane review pooled 73 randomized trials with 12,212 participants comparing GnRH antagonists with a long agonist approach (Al-Inany et al., 2016). Live birth showed no conclusive difference (odds ratio 1.02, 95% CI 0.85 to 1.23). OHSS of any grade was less common with antagonists (odds ratio 0.61, 95% CI 0.51 to 0.72).
We found no NCT numbers for these early trials.
What side effects does the label list?
The label has no boxed warning. Its Table IV counts events in 794 treated subjects “without regard to causality.” The most frequent were gynecological abdominal pain (4.8%), fetal death (3.7%), headache (3.0%), OHSS (2.4%) and vaginal bleeding (1.8%). Injection site reaction and nausea each occurred in 1.1%.
Hypersensitivity reactions have been reported after approval, including anaphylaxis, angioedema and urticaria. The label says some occurred with the first exposure. Contraindications are hypersensitivity to ganirelix, its components, GnRH or GnRH analogs, and known or suspected pregnancy.
The label also describes an observational study of more than 1,000 newborns. It compared them with historical controls after GnRH agonist treatment. Congenital anomaly rates were comparable, and the label states that any causal relationship is unknown.
What is ganirelix’s regulatory status, and is it used in research?
Prescription drug. Ganirelix acetate is an FDA-approved prescription drug, with Drugs@FDA listing its marketing status as “Prescription.” DailyMed lists versions from Organon, Ferring and several generic makers (DailyMed search). In our search of FDA pages, we found no drug safety communication specific to ganirelix.
Sport. WADA’s 2026 Prohibited List does not name ganirelix. Its section S2.2.1 covers “testosterone-stimulating peptides in males.” It names GnRH and “its agonist analogues,” along with chorionic gonadotrophin, LH and kisspeptin. Athletes should check with their anti-doping organization. See our guide to peptides on the 2026 WADA list.
Research. ClinicalTrials.gov lists 105 studies with ganirelix as an intervention (ClinicalTrials.gov). Most concern infertility treatment. Others include Organon’s study monitoring congenital malformations, NCT00724789, and hormone physiology studies. Registry entries record study status, not proof of benefit.
For related compounds, see our guides to cetrorelix, degarelix and hCG, and our overview of peptide hormones.
Frequently asked questions about ganirelix
Is ganirelix a GnRH agonist or antagonist?
It is an antagonist. It blocks GnRH receptors, and the label reports no initial release of gonadotropins.
What brand names has ganirelix had?
It was first labeled in the US as Antagon in 1999. Today DailyMed lists ganirelix acetate from Organon and other makers, plus Fyremadel from Ferring.
How is ganirelix different from cetrorelix?
Both are GnRH antagonists with the same labeled purpose. Their labels list different substituted positions. Our cetrorelix guide covers that drug.
Is ganirelix banned by WADA?
WADA’s 2026 list does not name it. Section S2.2.1 covers GnRH and its agonist analogues in males. Athletes should check with their anti-doping organization.
What to know now
- Approval: first approved July 29, 1999; now sold as ganirelix acetate and Fyremadel.
- Labeled use: inhibiting premature LH surges during controlled ovarian hyperstimulation.
- Evidence: human trials found rare LH surges and less OHSS than with agonists.
- Safety: no boxed warning; hypersensitivity can occur with the first exposure.
- Sport: not named on WADA’s 2026 list.
What we’re watching
Revisions to the ganirelix and Fyremadel labels on DailyMed. Any update to the Cochrane review of GnRH antagonists. And WADA’s 2027 Prohibited List, which takes effect on January 1, 2027.